Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,335,040
  • Shares Outstanding, K 2,696,190
  • Annual Sales, $ 42,294 M
  • Annual Income, $ 6,220 M
  • 60-Month Beta 0.62
  • Price/Sales 5.20
  • Price/Cash Flow 13.63
  • Price/Book 8.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.06
  • Number of Estimates 3
  • High Estimate 1.09
  • Low Estimate 1.04
  • Prior Year 1.05
  • Growth Rate Est. (year over year) +0.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.81 +3.73%
on 02/20/19
82.12 -0.45%
on 03/04/19
+2.51 (+3.17%)
since 02/19/19
3-Month
70.89 +15.32%
on 12/24/18
82.12 -0.45%
on 03/04/19
+7.98 (+10.82%)
since 12/19/18
52-Week
52.83 +54.75%
on 04/03/18
82.12 -0.45%
on 03/04/19
+27.12 (+49.65%)
since 03/19/18

Most Recent Stories

More News
Clinical Trials for Leukemia Exhibiting Encouraging Advancements

Recent developments mentioned in industry sourced article from Medicalexpress.com, a research and technology news service, it was encouraging to see an optimistic headline in cancer treatments. One article...

AMRN : 19.23 (-0.36%)
MRK : 81.72 (+0.45%)
MBRX : 1.28 (+2.40%)
DARE : 1.95 (-7.14%)
PHAS : 5.73 (-8.03%)
Merck To Collaborate with GenScript to Accelerate Cell and Gene Therapy Industrialization in China

- Collaboration to build global-standard platform for plasmid and virus manufacturing in China

MRK : 81.72 (+0.45%)
Top Research Reports for Merck, Adobe & Broadcom

Top Research Reports for Merck, Adobe & Broadcom

AVGO : 299.45 (+1.91%)
AZN : 42.85 (+0.63%)
MRK : 81.72 (+0.45%)
ROST : 92.24 (+1.22%)
ADBE : 258.54 (+0.30%)
PSA : 217.20 (-0.26%)
IMMUNE DESIGN CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

Rigrodsky & Long, P.A.:

MRK : 81.72 (+0.45%)
IMDZ : 5.84 (unch)
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

JNJ : 138.56 (+1.01%)
MRK : 81.72 (+0.45%)
AGN : 154.10 (+2.16%)
RHHBY : 33.7900 (-0.21%)
PFE : 42.26 (+1.08%)
AstraZeneca Up This Year on New Drugs & Pipeline Progress

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

BAYRY : 19.7100 (+2.71%)
CELG : 89.09 (+1.25%)
AZN : 42.85 (+0.63%)
MRK : 81.72 (+0.45%)
New Treatment Option Now Available in Canada for Newly Diagnosed Patients with Advanced Lung Cancer

KEYTRUDA(® )(pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy Reduced the Risk of Death by Half Compared to Chemotherapy Alone

MRK : 81.72 (+0.45%)
BriaCell Welcomes BioPharma Industry Experts to its Board of Directors

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces...

BCTXF : 0.0960 (+14.01%)
BCT.VN : 0.120 (unch)
MRK : 81.72 (+0.45%)
Enigma Biomedical Group Signs License Agreement with Merck for Novel MK-6884 Imaging Agent

Enigma Biomedical Group (EBG) today announced an exclusive license agreement with Merck, known as MSD outside the US and Canada, for the global development and commercialization of MK-6884,...

MRK : 81.72 (+0.45%)
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

BAYRY : 19.7100 (+2.71%)
AZN : 42.85 (+0.63%)
MRK : 81.72 (+0.45%)
BMY : 49.90 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 82.28
1st Resistance Point 81.81
Last Price 81.72
1st Support Level 80.90
2nd Support Level 80.46

See More

52-Week High 82.12
Last Price 81.72
Fibonacci 61.8% 70.93
Fibonacci 50% 67.48
Fibonacci 38.2% 64.02
52-Week Low 52.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar